China has been administering experimental coronavirus vaccines to key workers since July, a government official has reportedly said.
Groups facing high infection risks, such as medical workers, have been given vaccinations under an "emergency use" programme.
China has not specified how many people have been vaccinated or which product has been given.
Zheng Zhongwei, the head of the National Health Commission’s science and technology centre, is said to have told state media organisation CCTV on Sunday that the government had authorised “emergency use” of a Sars-Cov-2 vaccine for workers including health workers and border officials.
According to the Guardian, he said: “We’ve drawn up a series of plan packages, including medical consent forms, side-effect monitoring plans, rescuing plans, compensation plans, to make sure the emergency use is well regulated and monitored.”
Mr Zheng added that they planned to “scale up” the testing to other groups before autumn and winter.
The country has gone seven days without reporting a locally transmitted case.
Authorities could consider modestly expanding the emergency use programme to try to prevent outbreaks during the autumn and winter.
Before the official launch of the programme in July, China's military approved the use of CanSino's vaccine in June.
The World on Coronavirus lockdown
Meanwhile state media reported in June that employees at state-owned firms travelling overseas were allowed to take one of the two candidate vaccines being developed by CNBG.
Four of the world's seven vaccines that are in the third phase of trials are from China.
Two of the candidates are from China National Biotec Group (CNBG), a unit of state-owned pharmaceutical giant China National Pharmaceutical Group (Sinopharm).
Sinovac Biotech is developing the third candidate called CoronaVac, while CanSino Biologics is working with state military research unit Academy of Military Medical Sciences on Ad5-nCoV.
Argentina, Peru, Morocco, Bahrain and the United Arab Emirates have allowed CNBG to run Phase 3 trials. It's not immediately clear if the company's two vaccine candidates will be tested in those countries.
Indonesia and Brazil are helping with Phase 3 trials of Sinovac's CoronaVac, while Bangladesh aims to run a late stage clinical trial for the experimental vaccine.
Pakistan, Saudi Arabia and Russia have agreed to conduct Phase 3 trials of CanSino's candidate, while Mexico has signed an early agreement with the Chinese firm for a late-stage trial.